{"schema_version":"secwatch.filing_event.v1","accession":"0001323885-24-000013","form_type":"8-K","ticker":"ATRC","cik":"0001323885","company_name":"AtriCure, Inc.","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.760321+00:00","generated_at":"2026-06-06T00:51:23.335584+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AtriCure Q4 revenue $106.5M (+21%), full-year adj EBITDA positive $19.4M; guides 2024 rev ~$459-466M","bullets":["Q4 2023 revenue $106.5M (+21% YoY); full-year revenue $399.2M (+20.8%).","Full-year 2023 net loss improved $16M to $30.4M; adjusted EBITDA turned positive to $19.4M from -$2.2M.","Full-year diluted net loss per share $0.66 vs $1.02 in 2022; adjusted loss per share $0.75 vs $1.02.","2024 revenue guidance $459-$466M (15-17% growth); adjusted EBITDA $26-$29M (34-49% increase).","Over one million patients treated life to date; management cites broad-based expansion and momentum."],"urls":{"canonical":"https://secwatch.observer/filing/0001323885-24-000013","json":"https://secwatch.observer/filing/0001323885-24-000013.json","markdown":"https://secwatch.observer/filing/0001323885-24-000013.md","text":"https://secwatch.observer/filing/0001323885-24-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1323885/000132388524000013/0001323885-24-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1323885/000132388524000013/atrc-20240215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T00:51:23.335584+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c36a5f0b4b5dc4b5e56881e6b8901f754b7165e","claim":"AtriCure, Inc. reported financial results for the fourth quarter and full-year ended December 31, 2023.","evidence_excerpt":"On February 15, 2024 , AtriCure, Inc. issued a press release regarding its financial results for the fourth quarter and full-year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1323885/000132388524000013/0001323885-24-000013-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full-year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}